Project Description: The broad, long-term objective of this research program is to develop general methods to conditionally regulate protein function at the level of the protein molecules rather than by targeting the precursor DNA or mRNA sequences that encode a particular protein of interest. This new technology should be completely specific for the targeted protein and should provide rapid and dose-dependent control of protein function using cell-permeable small molecules. Cells typically regulate protein expression levels by balancing the creation and degradation of protein molecules. The majority of existing perturbation methods such as transcriptional switches and RNAi focus on protein synthesis, however when synthesis is switched off there is inevitably an experimental delay as the existing protein must be degraded. This research proposal takes a fundamentally different approach by focusing on methods to conditionally target specific proteins for degradation. The goal is to engineer small protein domains that are rapidly and constitutively degraded when expressed in mammalian cells. Importantly, the instability of a destabilizing domain is faithfully conferred to other proteins fused to these small domains. Addition of a cell-permeable ligand that binds tightly to the destabilizing domains shields them from degradation, allowing the fused proteins to perform their cellular functions. The genetic fusion of the destabilizing domain to the gene-of-interest ensures specificity, and the attendant small-molecule control confers speed, reversibility and dose-dependence to this method.
The specific aims of this proposal focus on developing new destabilizing domains that provide conditional control of protein expression to membrane-bound proteins expressed in mammalian cells as well as essential proteins expressed in yeast. This technology will be used to conditionally regulate enzymes involved in epigenetic remodeling of differentiated cells. Relevance: The goal of this research is to develop general new methods to rapidly and reversibly regulate the expression of specific proteins in eukaryotic cells. This methodology would enable the development of many new models for human diseases (including cultured cells or knock-out mice), and these model systems are enormously helpful in the ongoing search for new and improved drugs to treat human diseases. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM068589-06
Application #
7480307
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Jones, Warren
Project Start
2003-08-01
Project End
2011-05-31
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
6
Fiscal Year
2008
Total Cost
$339,124
Indirect Cost
Name
Stanford University
Department
Biology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Miyazaki, Yusuke; Imoto, Hiroshi; Chen, Ling-chun et al. (2012) Destabilizing domains derived from the human estrogen receptor. J Am Chem Soc 134:3942-5
Egeler, Emily L; Urner, Lorenz M; Rakhit, Rishi et al. (2011) Ligand-switchable substrates for a ubiquitin-proteasome system. J Biol Chem 286:31328-36
Rakhit, Rishi; Edwards, Sarah R; Iwamoto, Mari et al. (2011) Evaluation of FKBP and DHFR based destabilizing domains in Saccharomyces cerevisiae. Bioorg Med Chem Lett 21:4965-8
Iwamoto, Mari; Björklund, Tomas; Lundberg, Cecilia et al. (2010) A general chemical method to regulate protein stability in the mammalian central nervous system. Chem Biol 17:981-8
Edwards, Sarah R; Wandless, Thomas J (2010) Dicistronic regulation of fluorescent proteins in the budding yeast Saccharomyces cerevisiae. Yeast 27:229-36
Sellmyer, Mark A; Thorne, Steve H; Banaszynski, Laura A et al. (2009) A general method for conditional regulation of protein stability in living animals. Cold Spring Harb Protoc 2009:pdb.prot5173
Hagan, Emily L; Banaszynski, Laura A; Chen, Ling-chun et al. (2009) Regulating protein stability in mammalian cells using small molecules. Cold Spring Harb Protoc 2009:pdb.prot5172
Sellmyer, Mark A; Stankunas, Kryn; Briesewitz, Roger et al. (2007) Engineering small molecule specificity in nearly identical cellular environments. Bioorg Med Chem Lett 17:2703-5
Edwards, Sarah R; Wandless, Thomas J (2007) The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem 282:13395-401
Bayle, J Henri; Grimley, Joshua S; Stankunas, Kryn et al. (2006) Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity. Chem Biol 13:99-107

Showing the most recent 10 out of 16 publications